Brokerages Expect CRISPR Therapeutics (CRSP) Will Announce Earnings of -$0.67 Per Share

Wall Street analysts forecast that CRISPR Therapeutics (NASDAQ:CRSP) will announce earnings of ($0.67) per share for the current quarter, according to Zacks. Two analysts have made estimates for CRISPR Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.60) and the lowest estimate coming in at ($0.74). CRISPR Therapeutics posted earnings of ($0.54) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 24.1%. The firm is expected to announce its next earnings report on Thursday, May 10th.

On average, analysts expect that CRISPR Therapeutics will report full-year earnings of ($2.82) per share for the current fiscal year, with EPS estimates ranging from ($3.31) to ($2.53). For the next financial year, analysts expect that the company will report earnings of ($3.01) per share, with EPS estimates ranging from ($3.90) to ($2.27). Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for CRISPR Therapeutics.

How to Become a New Pot Stock Millionaire

A number of brokerages have recently commented on CRSP. Zacks Investment Research raised shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 13th. SunTrust Banks reissued a “buy” rating and issued a $65.00 price target on shares of CRISPR Therapeutics in a report on Friday, March 9th. Piper Jaffray reissued an “overweight” rating and issued a $53.70 price target (down previously from $67.00) on shares of CRISPR Therapeutics in a report on Friday, March 9th. Barclays increased their price target on shares of CRISPR Therapeutics from $29.00 to $59.00 and gave the stock an “overweight” rating in a report on Wednesday, March 7th. Finally, TheStreet raised shares of CRISPR Therapeutics from a “d+” rating to a “c” rating in a report on Friday, March 16th. Five investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $63.95.

In other news, insider Tyler Dylan-Hyde sold 66,000 shares of the company’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $28.03, for a total value of $1,849,980.00. Following the completion of the sale, the insider now owns 25,204 shares of the company’s stock, valued at approximately $706,468.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 39.98% of the stock is currently owned by corporate insiders.

Several institutional investors have recently made changes to their positions in the company. Wells Fargo & Company MN boosted its stake in shares of CRISPR Therapeutics by 17.2% in the 4th quarter. Wells Fargo & Company MN now owns 21,517 shares of the company’s stock valued at $505,000 after purchasing an additional 3,165 shares in the last quarter. ARK Investment Management LLC boosted its stake in shares of CRISPR Therapeutics by 22.8% in the 4th quarter. ARK Investment Management LLC now owns 31,388 shares of the company’s stock valued at $737,000 after purchasing an additional 5,833 shares in the last quarter. Creative Planning purchased a new stake in shares of CRISPR Therapeutics in the 4th quarter valued at $243,000. Paloma Partners Management Co purchased a new stake in shares of CRISPR Therapeutics in the 4th quarter valued at $290,000. Finally, D.A. Davidson & CO. purchased a new stake in shares of CRISPR Therapeutics in the 4th quarter valued at $370,000. 26.61% of the stock is owned by institutional investors.

Shares of NASDAQ:CRSP traded up $0.60 during trading on Friday, reaching $43.27. The company had a trading volume of 2,771,686 shares, compared to its average volume of 1,142,825. The firm has a market capitalization of $2,012.61, a price-to-earnings ratio of -25.30 and a beta of 3.56. CRISPR Therapeutics has a 12 month low of $13.50 and a 12 month high of $61.24.

ILLEGAL ACTIVITY WARNING: “Brokerages Expect CRISPR Therapeutics (CRSP) Will Announce Earnings of -$0.67 Per Share” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.tickerreport.com/banking-finance/3339301/brokerages-expect-crispr-therapeutics-crsp-will-announce-earnings-of-0-67-per-share.html.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.

Get a free copy of the Zacks research report on CRISPR Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Durect  to Release Quarterly Earnings on Wednesday
Durect to Release Quarterly Earnings on Wednesday
Auburn National Bancorporation  Posts  Earnings Results
Auburn National Bancorporation Posts Earnings Results
Summit State Bank  Announces  Earnings Results
Summit State Bank Announces Earnings Results
HFF  Issues Quarterly  Earnings Results, Misses Estimates By $0.14 EPS
HFF Issues Quarterly Earnings Results, Misses Estimates By $0.14 EPS
Sensient Technologies  Issues FY18 Earnings Guidance
Sensient Technologies Issues FY18 Earnings Guidance
GEA Group  PT Set at €34.00 by Baader Bank
GEA Group PT Set at €34.00 by Baader Bank


© 2006-2018 Ticker Report. Google+.